Last reviewed · How we verify
M28z1XXPD1DNR CAR
M28z1XXPD1DNR CAR is a Biologic drug developed by Memorial Sloan Kettering Cancer Center. It is currently in Phase 1 development.
At a glance
| Generic name | M28z1XXPD1DNR CAR |
|---|---|
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer (PHASE1)
- Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- M28z1XXPD1DNR CAR CI brief — competitive landscape report
- M28z1XXPD1DNR CAR updates RSS · CI watch RSS
- Memorial Sloan Kettering Cancer Center portfolio CI
Frequently asked questions about M28z1XXPD1DNR CAR
What is M28z1XXPD1DNR CAR?
M28z1XXPD1DNR CAR is a Biologic drug developed by Memorial Sloan Kettering Cancer Center.
Who makes M28z1XXPD1DNR CAR?
M28z1XXPD1DNR CAR is developed by Memorial Sloan Kettering Cancer Center (see full Memorial Sloan Kettering Cancer Center pipeline at /company/memorial-sloan-kettering-cancer-center).
What development phase is M28z1XXPD1DNR CAR in?
M28z1XXPD1DNR CAR is in Phase 1.
Related
- Manufacturer: Memorial Sloan Kettering Cancer Center — full pipeline
- Compare: M28z1XXPD1DNR CAR vs similar drugs
- Pricing: M28z1XXPD1DNR CAR cost, discount & access